EVITA登革热:一项评估感染沃尔巴克氏体的埃及伊蚊降低巴西虫媒病毒感染发病率效力的整群随机对照试验
EVITA登革热试验(DMID 17-0111)是在巴西贝洛奥里藏特开展的整群随机对照试验,以小学学区为整群,58个整群按1:1随机分配至释放感染沃尔巴克氏体(Wolbachia pipientis)的埃及伊蚊组或不释放的对照组。纳入3480名6-11岁儿童,每年进行虫媒病毒感染血清学监测,主要目标是比较两组间的虫媒病毒感染血清学发病率。
要点
- 58个小学学区整群按1:1随机分配至释放感染沃尔巴克氏体的埃及伊蚊组或不释放的对照组。
- 纳入3480名6-11岁在校儿童,每年进行虫媒病毒感染血清学监测。
- 主要目标为比较两组间的虫媒病毒感染血清学发病率。
核心结论
- 该试验旨在确定释放感染沃尔巴克氏体的蚊子降低埃及伊蚊传播的虫媒病毒感染人类的效果,并将补充来自大规模野外释放和正在进行的试验的越来越多证据。
研究设计与样本
- DMID 17-0111是一项在巴西贝洛奥里藏特开展的整群随机对照试验,整群按小学学区定义,共58个整群按1:1随机分配至干预组(释放感染沃尔巴克氏体pipientis的埃及伊蚊)或对照组(不释放)。
- 标准媒介控制活动(即杀虫剂和减少蚊虫滋生地的教育运动)将按该市当前做法继续开展。
- 参与者为3480名6-11岁儿童(每整群60名),就读于定义整群的学校且居住在该整群边界内,将接受年度虫媒病毒感染血清学监测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Arboviruses transmitted by Aedes aegypti including dengue, Zika, and chikungunya are a major global health problem, with over 2.5 billion at risk for dengue alone. There are no licensed antivirals for these infections, and safe and effective vaccines are not yet widely available. Thus, prevention of arbovirus transmission by vector modification is a novel approach being pursued by multiple researchers. However, the field needs high-quality evidence derived from randomized, controlled trials upon which to base the implementation and maintenance of vector control programs. Here, we report the EVITA Dengue trial design (DMID 17-0111), which assesses the efficacy in decreasing arbovirus transmission of an innovative approach developed by the World Mosquito Program for vector modification of Aedes mosquitoes by Wolbachia pipientis. METHODS: DMID 17-0111 is a cluster-randomized trial in Belo Horizonte, Brazil, with clusters defined by primary school catchment areas. Clusters (n = 58) will be randomized 1:1 to intervention (release of Wolbachia-infected Aedes aegypti mosquitoes) vs. control (no release). Standard vector control activities (i.e., insecticides and education campaigns for reduction of mosquito breeding sites) will continue as per current practice in the municipality. Participants (n = 3480, 60 per cluster) are children aged 6-11 years enrolled in the cluster-defining school and living within the cluster boundaries who will undergo annual serologic surveillance for arboviral infection. The primary objective is to compare sero-incidence of arboviral infection between arms. DISCUSSION: DMID 17-0111 aims to determine the efficacy of Wolbachia-infected mosquito releases in reducing human infections by arboviruses transmitted by Aedes aegypti and will complement the mounting evidence for this method from large-scale field releases and ongoing trials. The trial also represents a critical step towards robustness and rigor for how vector control methods are assessed, including the simultaneous measurement and correlation of entomologic and epidemiologic outcomes. Data from this trial will inform further the development of novel vector control methods. TRIAL REGISTRATION: ClinicalTrials.gov NCT04514107 . Registered on 17 August 2020 Primary sponsor: National Institute of Health, National Institute of Allergy and Infectious Diseases.
引用
- Collins MH, Potter GE, Hitchings MDT, et al. EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil. Trials. 2022. PMID: 35236394. doi:10.1186/s13063-022-05997-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。